Effects of the gut microbiota on bone mass

Trends in Endocrinology and Metabolism

Volumn 26, Issue 2, 2015, Pages 69-74

  Ohlsson, Claes ^a   Sjögren, Klara ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Gut microbiota; Osteoimmunology; Osteoporosis

Indexed keywords

ANTIBIOTIC AGENT; CARBOXY TERMINAL TELOPEPTIDE; CYTOKINE; GALACTOSE OLIGOSACCHARIDE; INULIN; LEUPRORELIN; PENICILLIN DERIVATIVE; PREBIOTIC AGENT; PROBIOTIC AGENT; SEROTONIN; SEX HORMONE;

ANTIBIOTIC THERAPY; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE STRENGTH; CALCIUM ABSORPTION; CALCIUM METABOLISM; CD4+ T LYMPHOCYTE; CORTICAL BONE; DYSBIOSIS; ENVIRONMENTAL FACTOR; FRAGILITY FRACTURE; HUMAN; IMMUNE STATUS; IMMUNE SYSTEM; IMMUNOSTIMULATION; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; INTESTINE LYMPHATIC TISSUE; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS REUTERI; MUCOSAL IMMUNITY; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TRABECULAR BONE; ANATOMY AND HISTOLOGY; ANIMAL; BONE; IMMUNOLOGY; INTESTINE; METABOLISM; MICROBIOLOGY; MICROFLORA; ORGAN SIZE; PHYSIOLOGY; RISK FACTOR;

ANIMALS; BONE AND BONES; BONE DENSITY; HUMANS; INTESTINES; MICROBIOTA; ORGAN SIZE; OSTEOPOROSIS; RISK FACTORS;

EID: 84923071266     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2014.11.004     Document Type: Review

References (56)

1. Sambrook P., Cooper C. Osteoporosis. Lancet 2006, 367:2010-2018.
2. Lu Y., et al. Classification of osteoporosis based on bone mineral densities. J. Bone Miner. Res. 2001, 16:901-910.
3. Ralston S.H., Uitterlinden A.G. Genetics of osteoporosis. Endocr. Rev. 2010, 31:629-662.
4. Qin J., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65.
5. Antonopoulos D.A., et al. Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect. Immun. 2009, 77:2367-2375.
6. Dethlefsen L., Relman D.A. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl. Acad. Sci. U.S.A. 2011, 108(Suppl. 1):4554-4561.
7. Kau A.L., et al. Human nutrition, the gut microbiome and the immune system. Nature 2011, 474:327-336.
8. Blumberg R., Powrie F. Microbiota, disease, and back to health: a metastable journey. Sci. Transl. Med. 2012, 4. Published online June 6, 2012. 10.1126/scitranslmed.3004184.
9. Tremaroli V., Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012, 489:242-249.
10. Maynard C.L., et al. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012, 489:231-241.
11. Peterson D.A., et al. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe 2008, 3:417-427.
12. Willing B.P., et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 2010, 139:1844-1854.
13. Lepage P., et al. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology 2011, 141:227-236.
14. Willing B., et al. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm. Bowel Dis. 2009, 15:653-660.
15. Sokol H., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:16731-16736.
16. Andoh A., et al. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease. J. Gastroenterol. 2012, 47:1298-1307.
17. Tojo R., et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J. Gastroenterol. 2014, 20:15163-15176.
18. Brzozowska M.M., et al. Bariatric surgery, bone loss, obesity and possible mechanisms. Obes. Rev. 2013, 14:52-67.
19. Schmidt S., et al. Longitudinal assessment of bone mineral density in children and adolescents with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2012, 55:511-518.
20. Kearns A.E., et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev. 2008, 29:155-192.
21. Lorenzo J., et al. Osteoimmunology: interactions of the bone and immune system. Endocr. Rev. 2008, 29:403-440.
22. Kong Y.Y., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
23. Martin-Millan M., et al. The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol. Endocrinol. 2010, 24:323-334.
24. Nakamura T., et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007, 130:811-823.
25. Pasco J.A., et al. High-sensitivity C-reactive protein and fracture risk in elderly women. JAMA 2006, 296:1353-1355.
26. Ding C., et al. Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J. Clin. Endocrinol. Metab. 2008, 93:1952-1958.
27. Schett G., et al. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch. Intern. Med. 2006, 166:2495-2501.
28. Eriksson A.L., et al. High-sensitivity CRP is an independent risk factor for all fractures and vertebral fractures in elderly men: the MrOS Sweden study. J. Bone Miner. Res. 2014, 29:418-423.
29. Charatcharoenwitthaya N., et al. Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. J. Bone Miner. Res. 2007, 22:724-729.
30. Li J.Y., et al. Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:768-773.
31. Roggia C., et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:13960-13965.
32. Koenig J.E., et al. Succession of microbial consortia in the developing infant gut microbiome. Proc. Natl. Acad. Sci. U.S.A. 2011, 108(Suppl. 1):4578-4585.
33. Yatsunenko T., et al. Human gut microbiome viewed across age and geography. Nature 2012, 486:222-227.
34. Lahti L., et al. Tipping elements in the human intestinal ecosystem. Nat. Commun. 2014, 5. Published online July 8, 2014. 10.1038/ncomms5344.
35. Biagi E., et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS ONE 2010, Published online May 17, 2010. 10.1371/journal.pone.0010667.
36. Claesson M.J., et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc. Natl. Acad. Sci. U.S.A. 2011, 108(Suppl. 1):4586-4591.
37. Cho I., et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 2012, 488:621-626.
38. Cox L.M., et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 2014, 158:705-721.
39. Macpherson A.J., Harris N.L. Interactions between commensal intestinal bacteria and the immune system. Nat. Rev. Immunol. 2004, 4:478-485.
40. Sjogren K., et al. The gut microbiota regulates bone mass in mice. J. Bone Miner. Res. 2012, 27:1357-1367.
41. Li J-Y., et al. Gut microbiota plays a pivotal role in the bone loss induced by sex steroid deficiency. J. Bone Miner. Res. 2014, 29(Suppl. 1):1029.
42. Yadav V.K., et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008, 135:825-837.
43. Williams S., et al. Minocycline prevents the decrease in bone mineral density and trabecular bone in ovariectomized aged rats. Bone 1996, 19:637-644.
44. Pytlik M., et al. Effects of doxycycline on mechanical properties of bones in rats with ovariectomy-induced osteopenia. Calcif. Tissue Int. 2004, 75:225-230.
45. Cromwell G.L. Why and how antibiotics are used in swine production. Anim. Biotechnol. 2002, 13:7-27.
46. Sanders M.E., et al. An update on the use and investigation of probiotics in health and disease. Gut 2013, 62:787-796.
47. Gibson G.R., Roberfroid M.B. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J. Nutr. 1995, 125:1401-1412.
48. Bron P.A., et al. Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat. Rev. Microbiol. 2012, 10:66-78.
49. Mutus R., et al. The effect of dietary probiotic supplementation on tibial bone characteristics and strength in broilers. Poult. Sci. 2006, 85:1621-1625.
50. Lavasani S., et al. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS ONE 2010, Published online February 2, 2010. 10.1371/journal.pone.0009009.
51. Ohlsson C., et al. Probiotics protect mice from ovariectomy-induced cortical bone loss. PLoS ONE 2014, Published online March 17, 2014. 10.1371/journal.pone.0092368.
52. Britton R.A., et al. Probiotic L. reuteri treatment prevents bone loss in a menopausal ovariectomized mouse model. J. Cell. Physiol. 2014, 229:1822-1830.
53. McCabe L.R., et al. Probiotic use decreases intestinal inflammation and increases bone density in healthy male but not female mice. J. Cell. Physiol. 2013, 228:1793-1798.
54. Weaver C.M., et al. Galactooligosaccharides improve mineral absorption and bone properties in growing rats through gut fermentation. J. Agric. Food Chem. 2011, 59:6501-6510.
55. Whisner C.M., et al. Galacto-oligosaccharides increase calcium absorption and gut bifidobacteria in young girls: a double-blind cross-over trial. Br. J. Nutr. 2013, 110:1292-1303.
56. Abrams S.A., et al. A combination of prebiotic short- and long-chain inulin-type fructans enhances calcium absorption and bone mineralization in young adolescents. Am. J. Clin. Nutr. 2005, 82:471-476.